FDA & Government News

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 20, 2026

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Conexiant

May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Conexiant

April 14, 2026

FDA Approval Targets Rare Kidney Disease

Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.

Conexiant

April 07, 2026

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant

March 26, 2026

FDA Clears AI Guidance Tool for Mitral Repair

AI enhances real-time intraprocedural visualization and navigation.

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 13, 2026

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Conexiant

Medical Oddities: Ancient Practice Calms Modern BP

FDA & Government News

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

FDA Approves Baxdrostat for Resistant Hypertension

FDA Approval Targets Rare Kidney Disease

FDA Approves First Generic Versions of FARXIGA

Daily News

FDA Approval Advances Basal Insulin

FDA Clears AI Guidance Tool for Mitral Repair

St. Louis Pediatrician Gets 20-Year Sentence

Obesity Medications Get New Guidance

RSV Vaccine Eligibility Expands

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Medical Oddities: Ancient Practice Calms Modern BP

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

FDA & Government News

Daily News

Recommendations